Trial investigates estrogen therapy in COVID-19, infection prevention guidance for people with diabetes — top stories in endocrinology
Data show that men who contract COVID-19 are more likely to be intubated or die compared with women. In light of these findings, researchers launched a trial investigating whether a transdermal estrogen patch can reduce symptom severity compared with regular care among patients with COVID-19. It was the top story in endocrinology last week.
Another top story was about new recommendations endorsed by 50 global organizations on how to reduce the risk for COVID-19 among people with diabetes.
Read these and more top stories in endocrinology below:
Study investigates estrogen patch use to lessen COVID-19 complications
Healio spoke with experts about the role of estrogen in immune response, the sex-based differences in COVID-19 outcomes, and how “crosstalk” across specialties could drive new discoveries in the search for COVID-19 treatments. Read more.
Recommendations for people with diabetes during COVID-19
JDRF and Beyond Type 1 released new guidance for people with diabetes on ways to reduce risk for contracting COVID-19 and curb the spread of disease, with 50 global diabetes organizations endorsing the recommendations, according to a press release. Read more.
Endocrine research spurs synthetic antibody development for COVID-19
A team of researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with GenScript, are developing a synthetic antibody to SARS-CoV-2, the virus that causes COVID-19. This antibody is intended to block the virus from entering human lung cells, and, if successful in trials, could be a potential treatment option for patients infected with the novel coronavirus. Read more.
Adults with active brown fat show ‘distinct fuel metabolism’ after cold exposure
A small cohort of healthy adults with brown adipose tissue expended 15% more energy after a cold exposure challenge compared with adults who did not have brown adipose tissue, according to findings published in The Journal of Clinical Endocrinology & Metabolism. Read more.
CV outcomes decline, but greater all-cause mortality persists in type 2 diabetes
People with type 2 diabetes are experiencing fewer cardiovascular complications today compared with 1990s data; however, greater all-cause mortality persists among those with diabetes compared with those without the disease, according to a longitudinal analysis of Australian adults published in The Journal of Clinical Endocrinology & Metabolism. Read more.